139 related articles for article (PubMed ID: 22862168)
21. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Dai QB; Zhu ZG
Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(1):40-4. PubMed ID: 16620646
[TBL] [Abstract][Full Text] [Related]
22. Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth
Liu K; Fang L; Sun H; Pan Z; Zhang J; Chen J; Shao X; Wang W; Tan Y; Ding Z; Ao L; Wu C; Liu X; Li H; Wang R; Su W; Li H
Mol Cancer Ther; 2018 May; 17(5):988-1002. PubMed ID: 29483218
[TBL] [Abstract][Full Text] [Related]
23. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Jemaà M; Kifagi C; Serrano SS; Massoumi R
Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
[TBL] [Abstract][Full Text] [Related]
24. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
[TBL] [Abstract][Full Text] [Related]
25. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
[TBL] [Abstract][Full Text] [Related]
26. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
Deng H; Jiang Q; Yang Y; Zhang S; Ma Y; Xie G; Chen X; Qian Z; Wen Y; Li J; Yang J; Chen L; Zhao X; Wei Y
Cancer Biol Ther; 2011 Feb; 11(4):401-9. PubMed ID: 21150280
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.
Chen XH; Lan B; Qu Y; Zhang XQ; Cai Q; Liu BY; Zhu ZG
World J Gastroenterol; 2006 Jan; 12(1):29-35. PubMed ID: 16440413
[TBL] [Abstract][Full Text] [Related]
28. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
29. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM
Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247
[TBL] [Abstract][Full Text] [Related]
31. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Knipstein J; Dubuc A; Taylor MD; Handler MH; Foreman NK; Vibhakar R
BMC Cancer; 2012 Mar; 12():80. PubMed ID: 22390279
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
Yunoki T; Tabuchi Y; Hayashi A; Kondo T
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
35. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
[TBL] [Abstract][Full Text] [Related]
36. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
[TBL] [Abstract][Full Text] [Related]
37. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.
Han DP; Zhu QL; Cui JT; Wang PX; Qu S; Cao QF; Zong YP; Feng B; Zheng MH; Lu AG
Med Sci Monit; 2012 Jun; 18(6):BR237-46. PubMed ID: 22648245
[TBL] [Abstract][Full Text] [Related]
38. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.
Koga K; Hattori Y; Komori M; Narishima R; Yamasaki M; Hakoshima M; Fukui T; Maitani Y
Cancer Sci; 2010 Apr; 101(4):941-7. PubMed ID: 20704575
[TBL] [Abstract][Full Text] [Related]
39. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
Ha GH; Kim DY; Breuer EK; Kim CK
Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]